Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病 骨髓增生异常综合征 的治疗。 其2009年的销售额为17亿美元。

Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.

youdao